References
- Hamed KM, Dighriri IM, Baomar AF, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022;14(9):e29518.
- Raharja A, Mahil SK, Baker JN, Psoriasis: a brief overview. Clin Med. 2021; 21(3): 170-173.
- Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;122(2):377-85.
- Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench Z, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: A population-based study. J Invest Dermatol. 2018;138(4):760–7.
- Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2021;82(6):1445–86.
- Al-Dabagh A, Davis SA, Kinney MA, et al. The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. Am J Clin Dermatol. 2013;14(2):155–61.
- Amoroso M, Augustin S, Moosmang S, Gashaw I. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review. J Mol Med (Berl). 2024;102(7):841-58.
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542.
- Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology. 2021;458:152840.
- Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis Targets Ther. 2018;8:21–9.
- Ahmadzadeh A, Zamani N, Hassanian-Moghaddam H, Hadeiy SK, Parhizgar P. Acute versus chronic methotrexate poisoning: a cross-sectional study. BMC Pharmacol Toxicol. 2019;20(1):39.
- Ezhilarasan D. Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms. Toxicology. 2021;458:152840.
- Bath RK, Brar NK, Forouhar F, Wu GY. Methotrexate hepatotoxicity. J Dig Dis. 2014;15(10):517-24.
- Liu L, Liu S, Wang C, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol. 2019;25(5):197–202.
- Shahsavari K, Ardekani SS, Ardekani MRS, et al. Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complement Med Ther. 2025;25(1):134.
- Ghaffari AR, Noshad H, Ostadi A, Ghojazadeh M, Asadi P. The effects of milk thistle on hepatic fibrosis due to methotrexate in rat. Hepat Mon. 2011;11(6):464-468.
- Hagag AA, Elgamsy MA, El-Asy HM, Mabrouk MM. Protective role of silymarin on hepatic and renal toxicity induced by MTX-based chemotherapy in children with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2016;8(1):e2016043.
- Mózes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(8):704-713.
- Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-1501.
- Miyata M, Kuroda M, Unakami M, Tasaki K, Migita K, Ohira H. Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Mod Rheumatol. 2019;29(6):936-942.
- Kianmehr N, Hashemi H, Davatchi F, Karami M, Mahmoudi M. Comparative evaluation of Fibrosis-4 index and FibroScan for liver fibrosis estimation among psoriatic arthritis patients on methotrexate. Govaresh. 2025;29(1):30-37.
- Lee JHM, Loo CH, Tan WC, Lee CK, Jamil A, Khor YH. Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients. Dermatologic Therapy. 2022; 35(1):e15203.
- Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatol. 2014;150(8):856-62.
- Khan S, Subedi D, Chowdhury MM. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis [published correction appears in Postgrad Med J. 2006 Aug;82(970):482]. Postgrad Med J. 2006;82(967):353-4.